Skip to main content

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Recruiting · Phase 2 · NCT05519475

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

At a glance

Research payments reported, 2025
$4.2M
U.S. investigators named
54
Sites paid
42
Planned or actual enrollment
120

About the trial

Sponsor
Regeneron Pharmaceuticals
Tested
ALN-HSD (drug), Placebo (drug)
Dates
Started 2023-02-09; completion 2028-12-07
Results posted
Not yet

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring related to MASH. The study is looking at several other research questions, including: …

From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $4.2M in research payments for this study in 2025 (1,108 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Pinnacle Clinical Research LLC $548,995
  • Geisinger Clinic $437,583
  • Adobe Clinical Research LLC $401,384
  • The Institute for Liver Health II LLC $250,605
  • Evolution Clinical Trials $176,774
  • Ark Clinical Research LLC $169,621
  • Tandem Clinical Research Gi LLC $147,727
  • South Texas Research Institute $146,845
  • Pioneer Research Solutions Inc $143,704
  • Texas Digestive Disease Consultants PLLC $141,291
  • Med Research of Florida LLC $136,432
  • California Liver Research Center $126,180
  • Indiana University $107,850
  • Charter Research LLC $103,350
  • Fundacion De Investigacion De Diego Inc $97,827
  • Advanced Medical Trials Georgetown LLC $94,864
  • Richmond Institute for Veterans Research $81,169
  • American Research Corporation $66,256
  • Methodist Dallas Medical Center, TX $60,478
  • California Liver Research Institute $59,396
  • $58,238
  • Del Sol Research Management LLC $55,725
  • Velocity Clinical Research Inc $46,128
  • Synergy Healthcare $44,759
  • Southern California Research Center $42,966
  • Hospital of Univ of Pennsylvania, PA $41,667
  • Pennsylvania State University $41,420
  • Inland Empire Clinical Trials LLC $40,968
  • University of Virginia Medical Center, VA $38,608
  • Regents of the University of Colorado $37,713
  • Ima Evaluations LLC $36,733
  • Health Awareness Inc $36,726
  • Clinnova Research Solutions Corporation $31,086
  • Om Research LLC $27,684
  • Trustees of Columbia University in The City of New York $26,228
  • Knowledge Research Center $22,215
  • Deaconess Clinic Inc $22,170
  • Genoma Research Group Inc $21,490
  • Latin Clinical Trial Center Inc $16,016
  • US Associates in Research LLC $14,372
  • Cognitive Clinical Trials LLC $13,302
  • Klinical Investigations Group LLC $11,314
  • Glri McAllen LLC $500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.